XAGE-1b nonapeptide and application thereof

Abstract

The present invention discloses a XAGE-1b nonapeptide and an application thereof. A sequence of the XAGE-1b short peptide is GSRQKKIRI. CTLs induced by the XAGE-1b antigen peptide do not produce an immune response to testicular cells and only kill tumor cells. The induced CTL clones have a good tumor cell specific killing effect. At the same time, in process of establishing the CTLs, inventors find that the sieved XAGE-1b antigen peptide has appropriate affinity with HLA on DC cells and can effectively stimulate and induce the production of the specific CTLs, indicating that the XAGE-1b antigen peptide has a good potential as a polypeptide vaccine and a DC vaccine. By cloning a XAGE-1b antigen peptide-specific TCR gene, constructing a viral vector and transducing peripheral circulating CD8+ T cells, TCR gene-modified T cell (TCR-T) clones are obtained, also have the tumor cell specific killing effect similar to that of parental CTLs, and have good clinical transformation and practicalapplication prospects.

Description

technical field [0001] The invention relates to tumor-associated antigen peptides and applications thereof, in particular to tumor-associated antigen XAGE-1b short peptides and applications thereof. Background technique [0002] As we all know, T cell adoptive therapy for tumors is currently the most eye-catching technology, especially the application of receptor-engineered T cells (TCR-T) is becoming an exciting cancer treatment method, and it also has therapeutic effects on viral infections and autoimmune diseases. Wide application prospects. [0003] The human immune surveillance system plays an important role in the process of resisting tumor growth. The immune surveillance system achieves the purpose of inhibiting tumor growth by coordinating various types of immune cells, among which cytotoxic T cells (cytotoxic Tlymphocytes, CTLs) play an extremely important role and are the most important. Key killer effector cells. tumor antigen-specific CD8 + T cells can specifi...

AI Technical Summary

Problems solved by technology

In the technical scheme disclosed by CN102428102A, an attempt is made to intercept a part of the XAGE-1b antigen to induce humoral immunity or cellular immunity to the tumor, but the result is not satisfactory, and the length of the polypeptide is still not shorter than 16AA

Short peptides may also have the problem of poor specificity. How to obtain short peptides with good specificity and good immunogenicity is a very challenging task

[0011] CN106243213A, CN106279391A and CN106279392A disclose a series of XAGE-1b short peptides, which illustrate that it is feasible for short peptides to induce specific immune responses, but experimental data show that it needs further improvement

Images